New hope for leukemia patients stuck in treatment deadlock

NCT ID NCT06514534

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 32 times

Summary

This study tests a drug called asciminib in people with chronic myeloid leukemia (CML) who have a specific genetic change (T315I mutation) that makes standard treatments less effective. The goal is to see if asciminib can control the disease and improve outcomes for about 20 participants who have run out of other options. The drug is taken as a pill, and researchers will monitor how well it reduces leukemia cells over 12 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA (CML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Novartis Investigative Site
RECRUITING

Bordeaux, 33076, France
Novartis Investigative Site
RECRUITING

Lille, 59037, France
Novartis Investigative Site
RECRUITING

Lyon, 69373, France
Novartis Investigative Site
RECRUITING

Nantes, 44093, France
Novartis Investigative Site
RECRUITING

Paris, 75475, France
Novartis Investigative Site
RECRUITING

Vandœuvre-lès-Nancy, 54511, France

Conditions

Explore the condition pages connected to this study.

CHRONIC MYELOID LEUKEMIA (CML)